Although the data still needs to be scrutinized, Quebec company Medicago says its latest trial suggests the COVID-19 vaccine it's produced with GlaxoSmithKline is showing promise.

Their phase 3 clinical trial found the two-dose vaccine to be 71 per cent effective against most variants of COVID-19.

However, Omicron was not included as the variant wasn't known about when the trial was conducted.

Jamie Mauracher explains where the Canadian-made shot is now in the approval process and why it could help fight the pandemic beyond Canada.

For more info, please go to https://globalnews.ca/news/8430579/canadian-manufacturer-medicagos-covid-19-vaccine/

Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews #Medicago #COVID-19Vaccine